0000000000815612
AUTHOR
M. Ryan
showing 2 related works from this author
New national and regional bryophyte records, 66
2021
a The Natural History Museum, Cromwell Road, London, SW7 5BD, UK; b Department of Plant and Animal Production, Munzur University, Vocational School of Tunceli, Tunceli, Turkey; c International School of Advanced Studies, University of Camerino, Camerino (MC), Italy; d Grupo de Investigación Biología para la Conservación, Universidad Pedagógica y Tecnológica de Colombia, Colombia; e Botanical Survey of India, Central National Herbarium, Howrah, India; f Botanical Garden-Institute, Russian Academy of Science, Vladivostok, Russia; g Viale Rovereto, Trento, Italy; h Department of Botany, Kherson State University, Kherson, Ukraine; i Kherson Branch of Admiral Makarov University, Kherson, Ukraine…
Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A…
2013
International audience; Background & AimsTreatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy. We assessed the effects of these anemia management strategies on rates of sustained virologic response (SVR) and safety.MethodsPatients (n = 687) received 4 weeks of peginterferon and ribavirin followed by 24 or 44 weeks of boceprevir (800 mg, 3 times each day) plus peginterferon and ribavirin. Patients who became anemic (levels of hemoglobin approximately ≤10 g/dL) during the study treatment period (n = 500) were assigned to groups that were managed by ribavi…